Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
CA 2344696 A1 · Owner: Voorhees, John J. · Inventors: Fisher, Gary J.; Voorhees, John J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The vitamin A metabolite all-trans retinoic acid (RA) is critical for normal skin function. Ultraviolet irradiation (UV) markedly reduces the mRNA and protein of the two major nuclear retinoid receptors RAR-.gamma. and RXR-, .alpha. in human skin in vivo. One half the dose of UV that causes skin reddening was sufficient to reduce retinoid receptor mRNA levels. Maximal reduction of RAR-.gamma. and RXR-.alpha. proteins occurred between 8 and 16 hours after UV irradiation. With multiple exposures to UV RXR-.alpha. , remained decreased, but RAR-.gamma. recovered to normal levels. Application of RA 24 hours before UV exposure partially prevented loss of nuclear retinoid receptors. UV …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 12, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 12, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 12, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.